Business Context and Reporting Period
This Form 8-K reports on the 2020 Annual Meeting of Stockholders held by Aquestive Therapeutics, Inc. on June 16, 2020. The filing details the final voting results for director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes
No material financial changes are reported in this document. The primary events are the election of Class II directors and the ratification of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2020.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a procedural report of shareholder voting results.
Important Facts for Investors
- Director Elections: Gregory B. Brown, M.D., and John S. Cochran were elected as Class II directors for a three-year term.
- Voting Results: Both director nominees received significant support, with approximately 13 million votes "For" each, though broker non-votes were substantial (9,667,660).
- Auditor Ratification: Stockholders ratified the appointment of KPMG LLP, with 23,010,926 votes "For" and 135,002 votes "Against."
- Emerging Growth Status: The company is identified as an emerging growth company.